Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 1/20 | 0.53 |
| ▸ | DCK | P27707 | 12/20 | 0.39 |
| ▸ | POLG | P54098 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.36 |
| ▸ | AHCY | P23526 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2036187 | 1.00 | ALB (0.53) | ALBDCKPOLGADRB1DNMT1 | |
| SCHEMBL6306806 | 0.89 | ALB (0.52) | ALBDCKPOLG | |
| SCHEMBL6303823 | 0.89 | ALB (0.52) | ALBDCKPOLG | |
| SCHEMBL12642437 | 0.85 | ALB (0.37) | ALBADRB1DNMT1LMNA | |
| SCHEMBL8997837 | 0.80 | TK1 (0.40) | ALBADRB1DNMT1LMNA | |
| SCHEMBL2640083 | 0.80 | TK1 (0.40) | ALBADRB1DNMT1LMNA | |
| SCHEMBL1956184 | 0.80 | ALB (0.52) | ALBDCKPOLGDNMT1LMNA | |
| SCHEMBL1956182 | 0.80 | ALB (0.52) | ALBDCKPOLGDNMT1LMNA | |
| SCHEMBL12162839 | 0.80 | ALB (0.52) | ALBDCKPOLGDNMT1LMNA | |
| SCHEMBL599407 | 0.79 | ALB (0.56) | ALBDCKPOLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0658166-A1 | ANTIVIRAL PYRIMIDINE NUCLEOSIDES | THE UNIVERSITY OF BIRMINGHAM (GB) | 1995-06-21 | — | — | EP | disclosed |
| WO-1994005687-A1 | ANTIVIRAL PYRIMIDINE NUCLEOSIDES | UNIVERSITY OF BIRMINGHAM (GB) | 1994-03-17 | — | — | WO | disclosed |